Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 9/20 | 0.77 |
| ▸ | EGFR | P00533 | 9/20 | 0.70 |
| ▸ | ITK | Q08881 | 4/20 | 0.70 |
| ▸ | BTK | Q06187 | 3/20 | 0.70 |
| ▸ | JAK2 | O60674 | 1/20 | 0.70 |
| ▸ | LYN | P07948 | 1/20 | 0.70 |
| ▸ | TEC | P42680 | 1/20 | 0.70 |
| ▸ | TXK | P42681 | 1/20 | 0.70 |
| ▸ | BMX | P51813 | 1/20 | 0.70 |
| ▸ | JAK3 | P52333 | 1/20 | 0.70 |
| ▸ | CD69 | Q07108 | 1/20 | 0.70 |
| ▸ | AURKA | O14965 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27020093 | 1.00 | SYK (0.77) | SYKEGFRITKBTKJAK2 | |
| SCHEMBL29665636 | 1.00 | SYK (0.77) | SYKEGFRITKBTKJAK2 | |
| SCHEMBL15814664 | 0.93 | SYK (0.66) | SYKEGFRITKBTKJAK2 | |
| SCHEMBL22909131 | 0.91 | SYK (0.70) | SYKEGFRITKBTKJAK2 | |
| SCHEMBL23409083 | 0.90 | SYK (0.77) | SYKEGFRITKBTKJAK2 | |
| SCHEMBL30150629 | 0.90 | SYK (0.77) | SYKEGFRITKBTKJAK2 | |
| SCHEMBL23388258 | 0.90 | SYK (0.77) | SYKEGFRITKBTKJAK2 | |
| SCHEMBL22909543 | 0.89 | SYK (0.69) | SYKEGFRITKBTKJAK2 | |
| SCHEMBL18737417 | 0.89 | SYK (0.67) | SYKEGFRITKBTKJAK2 | |
| SCHEMBL12519594 | 0.89 | EGFR (0.71) | SYKEGFRITKBTKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559454-B2 | Benzenesulfonamide derivatives and uses thereof | 2692372 ONTARIO, INC. (CA) | 2026-02-24 | — | — | US | disclosed |
| US-20240018153-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO, INC. (CA) | 2024-01-18 | — | — | US | disclosed |
| US-20240018153-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO, INC. (CA) | 2024-01-18 | — | — | US | disclosed |
| US-20240018153-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO, INC. (CA) | 2024-01-18 | — | — | US | disclosed |
| EP-4247794-A2 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 Ontario, Inc. (CA) | 2023-09-27 | — | — | EP | disclosed |
| CN-116745268-A | Benzenesulfonamide derivatives and uses thereof | 2692372安大略公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230055961-A1 | PENTAFLUOROBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | DUNAD THERAPEUTICS LTD. (GB) | 2023-02-23 | — | — | US | disclosed |
| US-20230055961-A1 | PENTAFLUOROBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | DUNAD THERAPEUTICS LTD. (GB) | 2023-02-23 | — | — | US | disclosed |
| US-20220281812-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO INC (CA) | 2022-09-08 | — | — | US | disclosed |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| US-8450335-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20130072469-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072469-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130065899-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065899-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2009158571-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS AND USES THEREOF (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | ABCG2, CYP3A43, CYP3A5 | SYK 2370/4885EGFR 1981/4885ITK 2697/4885 |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | SYK 2370/4885EGFR 1981/4885ITK 2697/4885 |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | SYK 610/4885EGFR 460/4885ITK 317/4885 |
| US-20130072469-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | SYK 2370/4885EGFR 1981/4885ITK 2697/4885 |
| US-12559454-B2 | Benzenesulfonamide derivatives and uses thereof | NR2E1, NR2C2, NR3C1 | SYK 2193/4885EGFR 572/4885ITK 4511/4885 |
| US-20230055961-A1 | PENTAFLUOROBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | FURIN, PFAS, CFTR | SYK 972/4885EGFR 308/4885ITK 1618/4885 |
| US-20130065899-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | SYK 2370/4885EGFR 1981/4885ITK 2697/4885 |
| US-20220281812-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | BCR, ARSA, VHL | SYK 1320/4885EGFR 2191/4885ITK 2485/4885 |
| US-20240018153-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | ABCG2, ABCB1, ARSA | SYK 610/4885EGFR 2252/4885ITK 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.